AstraZeneca plc (NYSE:AZN) – Stock analysts at Leerink Swann decreased their FY2019 earnings estimates for shares of AstraZeneca in a research report issued to clients and investors on Monday, Zacks Investment Research reports. Leerink Swann analyst S. Fernandez now anticipates that the company will earn $1.79 per share for the year, down from their previous estimate of $1.87. Leerink Swann currently has a “Market Perform” rating and a $38.00 price target on the stock. Leerink Swann also issued estimates for AstraZeneca’s FY2020 earnings at $2.17 EPS.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The business had revenue of $5.78 billion during the quarter, compared to analysts’ expectations of $5.49 billion. During the same quarter in the prior year, the business posted $1.21 earnings per share. AstraZeneca’s revenue was up 3.4% compared to the same quarter last year.
Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Sanford C. Bernstein upped their price objective on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Finally, ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $35.20.
AstraZeneca (AZN) traded down $0.09 on Thursday, reaching $33.93. 4,248,724 shares of the company traded hands, compared to its average volume of 4,503,337. AstraZeneca has a 1-year low of $28.43 and a 1-year high of $36.70. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The company has a market capitalization of $83,500.00, a PE ratio of 28.75, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74.
The company also recently disclosed a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be paid a $0.95 dividend. This represents a dividend yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. AstraZeneca’s dividend payout ratio is currently 116.10%.
Institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in shares of AstraZeneca by 7.6% in the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after buying an additional 310,389 shares during the period. Point72 Asset Management L.P. increased its stake in shares of AstraZeneca by 103.1% in the third quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock valued at $41,501,000 after buying an additional 621,831 shares during the period. Zions Bancorporation increased its stake in shares of AstraZeneca by 2,719.4% in the third quarter. Zions Bancorporation now owns 38,852 shares of the company’s stock valued at $1,317,000 after buying an additional 37,474 shares during the period. Wrapmanager Inc. increased its stake in shares of AstraZeneca by 21.1% in the third quarter. Wrapmanager Inc. now owns 52,340 shares of the company’s stock valued at $1,773,000 after buying an additional 9,120 shares during the period. Finally, Ingalls & Snyder LLC acquired a new position in shares of AstraZeneca in the fourth quarter valued at approximately $865,000. 14.75% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/16/astrazeneca-plc-azn-to-post-fy2019-earnings-of-1-79-per-share-leerink-swann-forecasts.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Get a free copy of the Zacks research report on AstraZeneca (AZN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.